Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Research

Effects of glucose and blood pressure control on diabetic kidney disease in old patients with type 2 diabetes

Authors: Tzu-En Wu, Yu-Hsin Chen, Harn-Shen Chen

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

Aims

We determined the influence of age on the effects of glucose and blood pressure control on diabetic kidney disease in patients with type 2 diabetes.

Methods

A total of 721 patients with type 2 diabetes, aged 41–85 years and with an estimated glomerular filtration rate (eGFR) ≥30 mL/ [min · 1.73 m2], were enrolled in this study between August 2001 and December 2002. All participants were followed up at our clinics until December 31, 2010. Primary outcomes were the development of end-stage renal disease (ESRD) and all-cause mortality. Secondary outcomes were the development of clinical albuminuria and a severe decline in eGFR.

Results

During the follow-up period (median: 8.3 years), 27 (3.7%) patients developed ESRD, 130 (18.0%) patients died without developing ESRD, and 16 (2.2%) patients died after developing ESRD. Mortality rate increased with age, but the incidence rate of ESRD did not. Poor glucose and blood pressure control was associated with the development of clinical albuminuria and with a severe decline in eGFR in younger patients with diabetes, but not in older patients. The development of severe decline in eGFR and ESRD was significantly lower in the middle tertile of blood pressure (i.e., SBP of 128–141 mm Hg) in older patients.

Conclusions

Adequate glucose and blood pressure control did not reduce the risk of ESRD; however, it may have delayed the onset of clinical albuminuria as well as eGFR decline in younger patients with type 2 diabetes.
Appendix
Available only for authorised users
Literature
2.
go back to reference Rosenstock J: Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging. 2001, 18: 31-44.CrossRefPubMed Rosenstock J: Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging. 2001, 18: 31-44.CrossRefPubMed
3.
go back to reference Brown AF, Mangione CM, Saliba D, Sarkisian CA, California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes: Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003, 51 (5 Suppl Guidelines): S265-S280.PubMed Brown AF, Mangione CM, Saliba D, Sarkisian CA, California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes: Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003, 51 (5 Suppl Guidelines): S265-S280.PubMed
4.
go back to reference Cayea D, Boyd C, Durso SC: Individualising therapy for older adults with diabetes mellitus. Drugs Aging. 2007, 24: 851-863.CrossRefPubMed Cayea D, Boyd C, Durso SC: Individualising therapy for older adults with diabetes mellitus. Drugs Aging. 2007, 24: 851-863.CrossRefPubMed
5.
go back to reference Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of Physicians: Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007, 147: 417-422.CrossRefPubMed Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of Physicians: Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007, 147: 417-422.CrossRefPubMed
6.
go back to reference American Diabetes Association: Standards of medical care in diabetes––2012. Diabetes Care. 2012, 35 (Suppl 1): S11-S63. American Diabetes Association: Standards of medical care in diabetes––2012. Diabetes Care. 2012, 35 (Suppl 1): S11-S63.
8.
go back to reference Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63: 225-232.CrossRefPubMed Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63: 225-232.CrossRefPubMed
9.
go back to reference UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853.CrossRef UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853.CrossRef
10.
go back to reference UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998, 317: 703-713.PubMedCentralCrossRef UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998, 317: 703-713.PubMedCentralCrossRef
11.
go back to reference von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007, 370: 1453-1457.CrossRefPubMed von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007, 370: 1453-1457.CrossRefPubMed
13.
go back to reference Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med. 2006, 354: 2473-2483.CrossRefPubMed Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med. 2006, 354: 2473-2483.CrossRefPubMed
14.
go back to reference Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH, FinnDiane Study Group: Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2011, 22: 537-544.PubMedCentralCrossRefPubMed Forsblom C, Harjutsalo V, Thorn LM, Wadén J, Tolonen N, Saraheimo M, Gordin D, Moran JL, Thomas MC, Groop PH, FinnDiane Study Group: Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol. 2011, 22: 537-544.PubMedCentralCrossRefPubMed
15.
go back to reference Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski AS, Eckfeldt JH, Warram JH, Krolewski AS: Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol. 2011, 22: 545-553.PubMedCentralCrossRefPubMed Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, Eckfeldt JH, Warram JH, Krolewski AS, Eckfeldt JH, Warram JH, Krolewski AS: Risk for ESRD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol. 2011, 22: 545-553.PubMedCentralCrossRefPubMed
16.
go back to reference Genuth S, Ismail-Beigi F: Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012, 97: 41-48.CrossRefPubMed Genuth S, Ismail-Beigi F: Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012, 97: 41-48.CrossRefPubMed
17.
go back to reference Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, et al: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010, 376: 419-430.PubMedCentralCrossRefPubMed Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, et al: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010, 376: 419-430.PubMedCentralCrossRefPubMed
19.
go back to reference Gordon I, Shurtleff D: Section 29. Means at Each Examination and Inter-Examination Variation of Specified Characteristics: Framingham Study, Exam 1 to Exam 10. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Edited by: Kannel WB, Gordon T. 1977, Washington DC: US Department of Health, Education, and Welfare (National Institutes of Health), 474-478. Gordon I, Shurtleff D: Section 29. Means at Each Examination and Inter-Examination Variation of Specified Characteristics: Framingham Study, Exam 1 to Exam 10. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Edited by: Kannel WB, Gordon T. 1977, Washington DC: US Department of Health, Education, and Welfare (National Institutes of Health), 474-478.
Metadata
Title
Effects of glucose and blood pressure control on diabetic kidney disease in old patients with type 2 diabetes
Authors
Tzu-En Wu
Yu-Hsin Chen
Harn-Shen Chen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-81

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue